Q-omics provides the consensus-scored MARCOL profile across patient tissues and cancer cell-line models. MARCOL expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MARCOL is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, MARCOL RNA expression shows 14,642 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, KICH, and GBM as cancer lineages where MARCOL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCOL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCOL survival associations across molecular data types. MARCOL RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCOL RNA expression–survival associations across cancer types. High MARCOL expression shows unfavorable associations in UCS, STAD, ACC and READ, but favorable associations in UCEC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for MARCOL RNA expression.
This table summarizes MARCOL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MARCOL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCOL shows lower tumor expression in KICH, LUSC, KIRP, BLCA, LUAD and THCA. The KICH box plot shows higher MARCOL RNA expression in normal versus tumor tissue (log2 FC = −0.245, t-test p = .002).
This table shows molecular features associated with MARCOL in patient tissues and cancer cell lines. In patient samples, MARCOL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCOL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE.
